ArticleScientific reports2026

Clinical benefit of palbociclib retreatment after abemaciclib exposure in hormone receptor positive, HER2 negative metastatic breast cancer.

Muhan Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.